If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
The epiphyseal arteries and osteogenic cells invade the epiphysis, depositing osteoclasts and osteoblasts which erode the cartilage and build bone, respectively. This occurs at both ends of long bones but only one end of digits and ribs.
== Safety issues == Care in package design is needed for food safety. A safety issue is that the cooking time given on the packaging does not apply to all microwave ovens. Setting the timer and coming back later, after the timer's alarm has sounded, could result in the popcorn being burnt and smoking badly. Microwave popcorn makers suggest that the person cooking the popcorn stay near the oven to observe the popcorn as it cooks, and take the popcorn out when the time between pops is more than a few seconds. Some microwave ovens have a specific mode designed for cooking popcorn, which either uses factory-calibrated time and power level settings, or which uses humidity or sound sensors to detect when popping has finished. The concern about microwave popcorn bags has increased in terms of the waste and their harmful impacts on the environment. The coating materials used in microwave popcorn bags can have negative effects on the environment. Researchers have detected toxic chemicals in the bags, such as perfluorinated compounds (PFCs) and their potential precursors.
=== Structure-activity experiments === When the 12-amino acid sequence of 'peptide 3'/CCL2 is aligned with the sequences of the other chemokines CCL3, CXCL8 and CXCL12 5 amino acids are conserved, Cys3, Asp5, Pro6, Trp10 and Gln12. In addition Val11 is also present in CCL3 and CXCL8. The corresponding 11th amino acid in CXCL12 is Ile. Ala4 in CCL2 is also present in CCL3 but the corresponding residue is Leu in CXCL8 and Ile in CXCL12. Inclusion of Leu at position 4 and Ile at position 11 (NH2-EICLDPKQKWIQ-OH) increased the inhibition potency of the peptide to 2-4μM. Removal of the first two residues from 'Peptide 3' (NH2-CADPKQKWVQ-OH) does not lower its BSCI potency. Peptide 3-Leu4, Ile11, the most potent BSCI peptide was chosen for further development. The first two amino acids were removed, and then according to the method of Jameson et al., the amino acid sequence was reversed and the amino acids replaced with D-amino acids. This combined transformation changes the orientation of the amides in the backbone but does not change the position of the amino acid sidechains. The peptide was then cyclised by adding a cysteine to the other end (HO-CLDPKQKWIQC-NH2), and oxidisation to form a disulfide bond to give NR58,3-14-3.
where w0 is total enthalpy. For a calorically perfect gas such as an ideal gas, the enthalpy is directly proportional to the temperature, and this leads to the concept of the total (or stagnation) temperature. When shock waves are present, in a reference frame in which the shock is stationary and the flow is steady, many of the parameters in the Bernoulli equation suffer abrupt changes in passing through the shock. The Bernoulli parameter remains unaffected. An exception to this rule is radiative shocks, which violate the assumptions leading to the Bernoulli equation, namely the lack of additional sinks or sources of energy.
Sources: en.wikipedia.org
=== Celebrity status === In 2008, Pudzianowski took part in the 7th season of Dancing with the Stars in his native Poland. He advanced to the final episode, but ultimately finished second, losing to actress Magdalena Walach. Pudzianowski was a contestant in the 1st season of the singing reality show Just the Two of Us in Poland. He was coupled with former Ich Troje singer Anna Wiśniewska.
Hancock, David (2001). The Mastiffs: The Big Game Hunters – Their History, Development and Future. Ducklington, Oxon: Charwynne Dog Features. ISBN 9780951780114. Fogle, Bruce (2009). The Encyclopedia of the Dog. New York: DK Publishing. ISBN 978-0-7566-6004-8. Encyclopædia Britannica (2019). "Mastiff: breed of dog". www.britannica.com. Encyclopædia Britannica, Inc. Retrieved 9 September 2019. Parker, Heidi G. (2012). "Chapter 3: The history and relationship of dog breeds". In Ostrander, Elaine A.; Ruvinsky, Anatoly (eds.). The Genetics of the Dog. Wallingford, Oxfordshire: CAPI books. pp. 38–53. ISBN 9781845939403. Oxford Dictionaries (2019). "Mastiff". Lexico.com. Oxford University Press. Retrieved 9 September 2019. Wynn, M. B. (1886). History of the Mastiff: Gathered from Sculpture, Pottery, Carvings, Paintings and Engravings. Melton Mowbray, William Loxley. ISBN 978-1-4465-4892-9. {{cite book}}: ISBN / Date incompatibility (help) Young, Amy; Bannasch, Danika (2007). "Chapter 4: Morphological variation in the dog". In Ostrander, Elaine A.; Giger, Urs; Lindblad-Toh, Kerstin (eds.). The Dog and its Genome. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. pp. 47–66. ISBN 9780879697815.
Normally pathogenic bacteria are weakened so they are no longer pathogenic. Commensal or food-grade bacteria which are not pathogenic. Using bacterial surface display of antigens is a valuable alternative to conventional vaccine design for various reasons, one of them being that the proteins expressed on the bacterial cell surface can act favourably as an adjuvant. Conventional vaccines require the addition of adjuvants. Another advantage of generating vaccines using bacterial display systems is that the whole bacterial cell can be incorporated in the live vaccine Unlike bacteriophage display systems which are generally used in vaccine development to find unknown epitopes, bacterial display systems are used to express known epitopes and the cells act as a vaccine delivery system.
Global hypomethylation results in decreased genomic stability, while local hypermethylation of tumour suppressor gene promoters often accounts for their loss of function. Specific patterns of methylation are indicative of specific cancer types, have prognostic value, and can help to guide the best course of treatment. Large-scale epigenome mapping efforts are under way around the world and have been organized under the Human Epigenome Project. This is based on a multi-tiered strategy, whereby bisulfite sequencing is used to obtain high-resolution methylation profiles for a limited number of reference epigenomes, while less thorough analysis is performed on a wider spectrum of samples. This approach is intended to maximize the insight gained from a given amount of resources, as high-resolution genome-wide mapping remains a costly undertaking. Gene-set analysis (for example using tools like DAVID and GoSeq) has been shown to be severely biased when applied to high-throughput methylation data (e.g. genome-wide bisulfite sequencing); it has been suggested that this can be corrected using sample label permutations or using a statistical model to control for differences in the numberes of CpG probes / CpG sites that target each gene.
== Further reading == FDA 21 CFR 113.3 Thermally processed low acid foods packaged in hermetically sealed containers Revision Apr. 2006 Potter, N. N. and Hotchkiss, J. H. Food Science (5th ed). Springer, 1999 Fellows, P. J. Food Processing Technology: Principles and Practice (2nd Edition). Woodhead Pub. 1999 Zeide, Anna (6 March 2018). Canned: The Rise and Fall of Consumer Confidence in the American Food Industry. University of California Press. ISBN 978-0520290686.
Sources: en.wikipedia.org
PKU is an autosomal recessive metabolic genetic disorder. As such, two PKU alleles are required for an individual to experience symptoms of the disease. For a child to inherit PKU, both parents must have and pass on the defective gene. If both parents are carriers for PKU, any child they have will have a 25% chance to be born with the disorder, a 50% chance the child will be a carrier, and a 25% chance the child will neither develop nor be a carrier for the disease. PKU is characterized by homozygous or compound heterozygous mutations in the gene for the hepatic enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. This enzyme is necessary to metabolize the amino acid phenylalanine (Phe) to the amino acid tyrosine. When PAH activity is reduced, Phe accumulates and is converted into phenylpyruvate (also known as phenylketone), which can be detected in the urine. Carriers of a single PKU allele do not exhibit symptoms of the disease, but appear to be protected to some extent against the fungal toxin ochratoxin A. Louis Woolf suggested that this accounted for the persistence of the allele in certain populations, in that it confers a selective advantage—in other words, being a heterozygote is advantageous. The gene for PAH is located on chromosome 12 in the bands 12q22-q24.2. As of 2000, around 400 disease-causing mutations had been found in the PAH gene. This is an example of allelic genetic heterogeneity.
=== Age-related macular degeneration === A Cochrane review concluded that there were no changes seen for risk of developing age-related macular degeneration (AMD) from long-term vitamin E supplementation and that supplementation may slightly increase the chances of developing late AMD.
=== Modulating fibrosis === Role of Thy-1 in fibrosis and fibroblast differentiation may have some tissue variation. Thy1 knock out mice have increased fibrosis in the lung. Fibrosis induced by chemotherapeutic agent Bleomycin is also increased in these mice.
== Distribution and habitat == This species is found in the Pacific Coast of Mexico, including the Gulf of California, and down through Central America to South America as far as the northern coast of Peru, as well as in eastern Pacific islands, including the Galápagos. They are found in shallow waters, roughly 0 to 40 m deep in rocky reefs, although 3 to 29 m are a preferred range. Additionally, reefs with sandy patches seem to be a preferred substrate. Within these depths, I. fuscus has been found to predominate areas where high amounts of Ulva sp. are located. The species tends to be more active at night as during the daytime they are cryptic and being active would make them more visible to predators.
== Export == GS-HNE is a potent inhibitor of the activity of glutathione S-transferase, and therefore must be shuttled out of the cell to allow conjugation to occur at a physiological rate. Ral-interacting GTPase activating protein (RLIP76, also known as Ral-binding protein 1), is a membrane-bound protein which has high activity towards the transport of GS-HNE from the cytoplasm to the extracellular space. This protein accounts for approximately 70% of such transport in human cell lines, while the remainder appears to be accounted for by Multidrug Resistance Protein 1 (MRP1).
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.